Department of Defense research grant · Biotech
Delix Therapeutics receives $825,000 defense grant for hearing-loss research
The U.S. Department of Defense award supports research into neuroplastogens and cochlear synapses.
Delix Therapeutics announced an $825,000 grant from the U.S. Department of Defense on June 4, 2024. The award supports research into a neuroplastogen intended to address hearing loss.
The work evaluates dosing in models of temporary and permanent hearing loss and studies the role of cochlear synapses in hearing recovery. Delix develops compounds designed to promote neural plasticity across psychiatric and neurological conditions.
Use of funds
Evaluate neuroplastogen dosing in hearing-loss models
Funding history
Department of Defense research grant · This round$825K
NIDA research grant$320KConvertible notes>$30MCredit facility option≤$10MSeries A$70M